These observations further support our hypothesis that the effect of CDC25 inhibition in primary human AML cells will differ between patients, and future biological as well as clinical studies therefore have to address the question whether CDC25 inhibition is effective for most or only a subset of AML patients. This evidence concerns the gene CDC25C and acute myeloid leukemia.